Amylyx Pharmaceuticals, Inc. (AMLX)
| Market Cap | 1.79B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -144.74M |
| Shares Out | 110.54M |
| EPS (ttm) | -1.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 622,181 |
| Open | 17.05 |
| Previous Close | 16.88 |
| Day's Range | 16.11 - 17.56 |
| 52-Week Range | 4.20 - 18.61 |
| Beta | -0.21 |
| Analysts | Strong Buy |
| Price Target | 21.56 (+33.38%) |
| Earnings Date | May 7, 2026 |
About AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phas... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for AMLX stock is "Strong Buy." The 12-month stock price target is $21.56, which is an increase of 33.38% from the latest price.
News
Amylyx Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
Avexitide, a GLP-1 antagonist for post-bariatric hypoglycemia, is in phase III trials with results expected in Q3 2025. Prior studies showed a 64% reduction in severe hypoglycemic events, and the company is targeting a 2027 launch for this first-in-class therapy.
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference.
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia.
Amylyx Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Avexitide, a GLP-1 receptor antagonist, is in a pivotal phase III trial for post-bariatric hypoglycemia, with prior studies showing strong efficacy and FDA breakthrough designation. Market research confirms a large orphan population, and future plans include label expansion and a long-acting formulation.
Amylyx Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Top-line results from the pivotal avexitide phase III trial in PBH are expected in Q3 2026, with NDA submission and commercialization targeted for 2027. The pipeline includes ALS and Wolfram syndrome programs, and a long-acting GLP-1 antagonist is in early development.
Amylyx Pharmaceuticals Earnings Call Transcript: Q4 2025
Advanced pipeline and completed LUCIDITY Phase III trial recruitment for Avexitide, with top-line data expected Q3 2026 and a strong cash position extending runway into 2028. Commercial launch preparations and expanded pipeline efforts continue amid significant unmet need in PBH.
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial and business results for the fourth quarter and full year ended Dece...
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences.
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026.
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest...
Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) recep...
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial.
Amylyx Pharmaceuticals Transcript: Citi Annual Global Healthcare Conference 2025
Avexitide is advancing through a pivotal Phase 3 trial for PBH, with commercialization targeted for 2027. The company is also developing long-acting GLP-1 inhibitors and expanding into ALS and Wolfram syndrome, leveraging strong clinical data and rare disease expertise.
Amylyx Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference
Avexitide is advancing in a pivotal phase III trial for PBH, with top-line results expected next year. PBH awareness and diagnosis are increasing, and educational efforts are planned to support market growth. The pipeline includes assets for Wolfram syndrome and ALS, with robust financial runway into 2028.
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Amylyx Pharmaceutica...
Amylyx Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Three clinical programs are advancing, with Avexetide in a pivotal phase 3 trial for PBH, targeting a significant unmet need. Strong prior data, robust FDA engagement, and a $344M cash position support a potential 2027 launch, with key trial results expected in Q3 next year.
Amylyx Pharmaceuticals Earnings Call Transcript: Q3 2025
Avexitide's phase III Lucidity trial for PBH is progressing with steady enrollment, now targeting Q1 2026 for recruitment completion and Q3 2026 for top-line data. Financials are strong with $344M in cash, supporting a planned 2027 launch and ongoing pipeline development.
Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial and business results for the third quarter ended September 30, 2025....
Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences.
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025.
Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciar...
AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders
Amylyx allegedly misled investors about Relyvrio's demand and growth, hiding high discontinuation rates and a fading launch surge that hurt its viability.
Amylyx Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Key programs include avexitide for PBH, AMX0035 for Wolfram syndrome, and AMX0114 for ALS, with major clinical milestones expected by year-end. Recent $175 million financing extends runway into 2027, supporting ongoing trials and future commercialization.
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,500,000 shares...